Review
Antisense strategies in dopamine receptor pharmacology
Life Sciences, v 60(7), pp 433-455
1997
PMID: 9042372
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Recent advances in molecular biology have rovided pharmacologists the opportunity of developing an entirely new type of agent for studying and treating a variety of biological disorders. These agents, termed antisense oligodeoxynucleotides, have as their target the messenger RNAs encoding specific proteins. They act by binding to selected portions of these mRNAs through complimentary interactions and thereby prevent the synthesis of these proteins. These novel pharmacological tools have the promise of being easier to design and being more selective and predictable in their actions. In addition, insofar as agents targeted to receptors for neurotransmitters are concerned, unlike the classical pharmacological agents, these new compounds may not lead to the upregulation of the very receptors the drugs are designed to inhibit.
Metrics
Details
- Title
- Antisense strategies in dopamine receptor pharmacology
- Creators
- Benjamin Weiss - Drexel UniversitySui-Po Zhang - Drexel UniversityLong-Wu Zhou - Drexel University
- Publication Details
- Life Sciences, v 60(7), pp 433-455
- Publisher
- Elsevier
- Resource Type
- Review
- Language
- English
- Academic Unit
- Pharmacology and Physiology
- Web of Science ID
- WOS:A1997WE69900001
- Scopus ID
- 2-s2.0-0031561793
- Other Identifier
- 991019169674904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Medicine, Research & Experimental
- Pharmacology & Pharmacy